Healthy Subject
4
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
InnoCareOrelabrutinib and placebo
HutchmedHMPL-523
CelltrionCT-P41
Hua MedicineHMS5552
Clinical Trials (4)
Total enrollment: 247 patients across 4 trials
Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
Start: Nov 2022Est. completion: Aug 202348 patients
Phase 1Unknown
A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers
Start: Jun 2022Est. completion: Sep 202239 patients
Phase 1Completed
Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects
Start: Oct 2021Est. completion: Oct 2022154 patients
Phase 1Completed
Human Mass Balance Study of HMS5552 in Healthy Subjects
Start: Mar 2017Est. completion: Apr 20176 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 companies competing in this space